Biopharma investors zero in on oncology and immunology

Biopharma investors are staying focused on the oncology and immunology sectors as major mergers fuel growth in those areas, according to an April 30 report from The Compass.

Advertisement

Changes in disease burden can influence mergers and acquisitions (M&A) activity in these sectors. The report found an increase in new patients associated with oncology providers in recent years. 

In March, Pfizer announced its intention to acquire cancer therapeutics company Seagen for $43 billion. The acquisition amount exceeds the prices of all of Pfizer’s acquisitions since 2019, according to the report.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.